The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Serum neurofilament light chain as an early disease biomarker in ATTR amyloidosis
In this video, Milou Berends, MD, PhD, University Medical Center Groningen, Groningen, the Netherlands, outlines recent findings on the use of serum neurofilament light chain (sNfL), a marker of neuronal damage, as an early disease biomarker for transthyretin (ATTR) amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
